Dyslipidaemia: Failure to THRIVE: the end for niacin?
Statins are established as first-line therapies for the prevention of cardiovascular disease (CVD); however, they do not completely eliminate the future risk of CVD events. Numerous studies have, therefore, focused on the role of combination lipid-lowering therapies to further reduce CVD events through additional reduction in the level of plasma LDL cholesterol or triglycerides, or through raising the level of HDL cholesterol.
Where can I read this paper?
Full article on Nature Reviews Cardiology: Note: you will need the credentials or your institution to login or you can purchase access.
Published: Nature Reviews Cardiology 10, 246-247 (May 2013) | doi:10.1038/nrcardio.2013.48